Company intelligence / Profile preview

RadAlliance Therapeutics

San Diego, California, United Statesradalliancetx.com ↗

Ownership: Private
Employees: ~4
Development stage: Other

Overview

RadAlliance Therapeutics is a clinical-stage targeted radionuclide therapy biotech focused on precision oncology. Founded in late 2024 and based in San Diego, the company is developing diagnostic and therapeutic nuclear medicines. Its disclosed pipeline includes PSMA-targeted radiopharmaceutical programs for prostate cancer, including an actinium-225 therapeutic candidate and a copper-64 imaging/diagnostic agent. The company appears to be focused on improving tumor retention and efficacy in radioligand therapy for metastatic castration-resistant prostate cancer.

Therapeutic areas: Oncology
Modalities: Radiopharmaceutical
Industry: Biotech

Drug pipeline

2 assets

Cu-RAX301

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on RadAlliance Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RadAlliance Therapeutics.

Explore the full profile